Posted inInternal Medicine news Oncology
Low-Dose Aspirin and Cancer Mortality in Older Adults: Long-Term ASPREE Results Challenge Previous Paradigms
A 10-year follow-up of the ASPREE trial reveals that low-dose aspirin does not reduce cancer incidence in adults aged 70 and older, but is associated with increased cancer-related mortality, challenging long-held assumptions about aspirin's chemopreventive benefits in geriatric populations.

















